ArticleFrontiers in oncology2026
Adrenal metastases of differentiated thyroid cancer: clinicopathological characteristics and prognostic factors.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the impact of adrenal metastases (AM) of differentiated thyroid cancer (DTC) through the comparison of clinicopathological characteristics and prognoses between DTC patients with AM and those with other distant metastatic sites. Methods: We retrospectively analyzed the records of 84 DTC patients (28 DTC patients with AM and 56 with other metastatic sites) who underwent surgery and Results: A total of 84 patients with DTC were enrolled in this study, among whom 28 were diagnosed with AM and 56 with distant metastases at other sites. All patients in both groups received radioactive iodine therapy. The proportion of radioactive iodine-refractory DTC (RAIR-DTC) was significantly higher in the DTC with AM (DTC-AM) group (71.43% vs. 44.64%). The median time of follow-up of the DTC patients with AM and those without was 29.6 months (5.0-112.5 months) and 69.3 months (10.4-146.7 months), respectively. At the end of follow-up, 10 patients (35.71%) died in the DTC-AM group, while 8 patients (14.29%) died in the non-DTC-AM group. The 5- and 10-year OS rates of the DTC-AM group were 65.31% and 46.65% versus 92.88% and 78.23% in the non-DTC-AM group. The presence of AM, advanced age at diagnosis of distant metastases (≥60y) and large maximal primary tumor size (≥4cm) were independently associated with poor survival (all P<0.05). Conclusion: Patients with DTC-AM are characterized by a higher proportion of advanced age at diagnosis of distant metastases, larger primary tumor size, a predominance of multiple synchronous distant metastatic sites, a higher rate of RAIR-DTC, and more frequent use of tyrosine kinase inhibitor therapy. AM exerted a significant negative impact on the prognoses of DTC patients. The occurrence of AM, advanced age at diagnosis of distant metastases (≥60y) and large maximal primary tumor size (≥4cm) were independent risk factors for unfavorable prognoses of DTC patients with distant metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.